MARKET NEWS

Sarepta Therapeutics Announces Positive & Robust Expression & Biomarker Data
SAMDI Tech Provides 1+ Million Compounds Through WuXi Partnership for Drug Candidate Screening
Foamix Announces Positive Results From Phase 3 Open-Label Safety Study Evaluating Topical Minocycline Foam
ABclonal Technology Partners With BenchSci to Boost Discoverability of its Novel Products
Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study
Nuvec: A Breakthrough Technology for mRNA/pDNA Delivery for Vaccines & Cancer Treatments

  FEATURED EDITORIAL

  COMPANY PROFILE


Vetter is a leading contract development and manufacturing organization (CDMO) that specializes in the aseptic filling of syringes, cartridges, and vials. Vetter holds numerous patents and has extensive experience with biologics and other complex compounds, including monoclonal antibodies, peptides, interferons, and vaccines. More than 80% of Vetter’s active projects are biologics, and Vetter currently manufactures 5 of the world’s top 10. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Rockland Immunochemicals & Cellaria Sign Worldwide Distribution Agreement

Rockland Immunochemicals & Cellaria Sign Worldwide Distribution Agreement

Cellaria, LLC recently announced a new distribution partnership with Rockland Immunochemicals, Inc. (Rockland) that gives Rockland the rights to market and sell Cellaria’s high-quality next generation in-vitro disease models and cell culture media worldwide.

AKCEA-APO(a)-LRx Advances as Novartis Exercises Option to License

AKCEA-APO(a)-LRx Advances as Novartis Exercises Option to License

Akcea Therapeutics, Inc. recently announced that Novartis has exercised its option to license AKCEA-APO(a)-LRx, a drug to treat patients with elevated levels of lipoprotein(a), or Lp(a), and established cardiovascular disease (CVD).

U.S. FDA Grants Breakthrough Therapy Designation to Amicus Therapeutics

U.S. FDA Grants Breakthrough Therapy Designation to Amicus Therapeutics

Amicus Therapeutics recently announced that the US FDA has granted to Amicus a Breakthrough Therapy Designation (BTD) to AT-GAA for the treatment of late onset Pompe disease, an inherited lysosomal storage disorder caused by the deficiency of an enzyme known as acid alpha-glucosidase (GAA).

SGS Appoints Biologics Manager at Expanded Life Sciences Facility in Illinois

SGS Appoints Biologics Manager at Expanded Life Sciences Facility in Illinois

SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, today announced the appointment of Dr. Haris Jamil as Biologics Manager of its recently expanded biopharmaceutical testing facility in Lincolnshire, Illinois, USA.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 13 – Particle Design Technology
March 20 – Analytical Instruments